TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Synchronized Intermittent Mechanical Ventilation Versus Open Lung Ventilation With Spontaneous Respiration

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* \>/=18 years of age, ISS \>/=25, on ventilator for more than 48 hours~Exclusion Criteria:~* less than 18 years of age, die or come off ventilator in less than 48 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open Lung Ventilation (Type: None): within 24 hours of arrival trauma patients with ISS \>25 will be randomized to BiVent (APRV)
- SIMV (Type: None): within 24 hours of arrival trauma patients with ISS \>25 will be randomized to either SIMV or BiVent

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Investigating a Novel Modifiable Factor Affecting Renal Function After Partial Nephrectomy: Cortical Renorrhaphy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
3.0 INCLUSION/EXCLUSION CRITERIA~3.1 Inclusion criteria:~* ≥ 18 years of age.~* Must provide written informed consent~* Presence of cT1 renal mass by diagnostic CT assessment.~* Scheduled for partial nephrectomy of renal mass.~* Expected survival of at least 3 months.~* ECOG ≤ 1.~* Negative serum/urine pregnancy test within 24 hours for females of child bearing age prior to surgery~* Recovered from toxicity of any prior therapy to grade 1 or better~* If biopsy of mass has been done, pathology must be consistent with RCC.~3.2 Exclusion criteria:~* Solitary kidney~* Multiple or bilateral renal masses when more than one mass is operated on at the same time or within 4-months of each other.~* Hepatic or renal toxicity (GFR \<30) greater than or equal to Grade 2 (using CTCAE version 4 standard definitions)~* Bleeding diathesis or inability to hold anticoagulation for surgery~* Participation in another investigational trial concurrently or within 30 days~* Significant acute or chronic medical, neurologic, or psychiatric illness in the subject that, in the judgment of the Principal Investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cortical renorrhaphy (Type: ACTIVE_COMPARATOR): Cortical renorrhaphy is performed after partial nephrectomy using a running barbed suture on MH (36mm) needle. Polymer locking clips are used to maintain tension. A base layer running stitch is performed prior to the cortical renorrhaphy.
- Non-renorrhaphy (Type: EXPERIMENTAL): The suture closure of the renal cortex after tumor removal is omitted. A base layer running stitch only is performed for hemostasis and urine leak prevention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study in the Treatment of Acute Mania

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of bipolar I disorder and currently display an acute manic or mixed episode (with or without psychotic features)~* Patients must have a Y-MRS total score of greater or equal to 20 at visit 2~* Patients must have experienced at least one manic or mixed episode prior to study enrollment~* Female of childbearing potential must be using a medically accepted means of contraception, or practice sexual abstinence~* Each patient must have a level of understanding sufficient to communicate intelligently with study personnel~* Patients must be considered reliable~* Each patient must understand the nature of the study and signed informed consent~Exclusion Criteria:~* Female patients who are pregnant or lactating~* Serious, unstable illnesses such that hospitalization for the disease is anticipated within 3 month or death is anticipated within 3 years~* Uncorrected hypothyroidism or hyperthyroidism~* Narrow-angle glaucoma~* History of allergic reactions or intolerance to study medications~* DSM-IV substance dependence within the past 30 days at the judgement of the investigator~* Judged clinically to be at serious suicidal risk~* Treatment with an injectable depot neuroleptic within less than one dosing interval between depot neuroleptic injections prior to visit 2~* Any patient treated with clozapine within 4 weeks prior to visit 2~* Subjects who have received treatment with ECT within one month prior to visit 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Patients will be given olanzapine
- B (Type: ACTIVE_COMPARATOR): Patients will be given either haloperidol or zuclopentixol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Erector Spinae Plane Block and Its Effect on Respiratory Status and Pain Management in Rib Fracture Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Blunt chest trauma~* Sustaining at least 3 unliateral rib fractures~* Resultant vital capacity less than 30% predicted~* Pain score reaches threshold despite using the current institutional standard of care for pain control~Exclusion Criteria:~* Patients whose weight less than 60kg.~* Patients with bilateral rib fractures.~* Patients that are intubated and mechanically ventilated.~* Pregnant Individuals.~* Any individual with a documented allergy to ropivacaine.~* Patients with limited English proficiency (LEP)~* Patients whose body habitus prevents the practitioner's ability to adequately perform the procedure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ESP block with normal saline (Type: SHAM_COMPARATOR): An erector spinae plane block will be performed and a single dose of Normal Saline Flush, 0.9% Injectable Solution will be administered into the target muscle plane.
- ESP block with local anesthetic (Type: EXPERIMENTAL): An erector spinae plane block will be performed and a single dose of 0.5% ropivacaine will be injected into the target muscle plane.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Basal-bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes (PININ Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Previous diagnosis of type 2 diabetes with a blood glucose level on admission greater than 180 mg/dl and treated with diet, any combination of oral antidiabetics agents and/or insulin therapy~Exclusion Criteria:~* Patients with hyperglycemia without a previous diagnosis of diabetes~* Patients with acute hyperglycemic emergencies or with severe hyperglycemia treated with intravenous insulin infusion on admission~* Patients with acute or chronic kidney disease (serum creatinine greater than 2 mg/dl),~* Patients treated with corticosteroids~* Patients with history of severe or repeated hypoglycemic episodes~* Pregnant women~* Patients expected to require ICU admission or less than 3 days of hospital stay

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Premixed insulin (Type: EXPERIMENTAL): Mixtard 30:70 Novonordisk® twice daily, before breakfast and before dinner.
- Basal-bolus (Type: EXPERIMENTAL): 'Lantus® once daily and Apidra® before meals

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Alterations of Immunologic Mediators During Severe Sepsis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age \>= 18 y~* agreement with study procedures~* 3 of 4 SIRS-criteria~* proven or highly suspected infection~* 2 or more sepsis-induced organ failures~* start of first sepsis-induced organ failure within the last 36 hours~Exclusion Criteria:~* non-agreement with study procedures~* signs of severe sepsis with organ failure \> 36 hours~* chronic immuno-compromising diseases~* chronic therapy with anti-inflammatory drugs~* non-curable cancer~* chronic renal failure with hemodialysis~* pregnancy or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Domperidone in Refractory Gastroparesis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female~* Age 18 and older~* Symptoms or manifestations secondary to motility disorders of the upper GI tract. These include gastroparesis, functional dyspepsia, gastroesophageal reflux disease that are refractory to standard therapy.~* Patients must have a comprehensive evaluation to eliminate other causes of their symptoms. This includes a history and physical examination. A recent (within 3 years) evaluation of the upper GI tract with either upper endoscopy or upper GI radiographic series. Baseline blood tests suggested are electrolytes, magnesium, and prolactin level.~* Patient has signed informed consent for the administration of domperidone that informs the patient of potential adverse events including:~  * Increased prolactin levels~ * Breast changes~ * Extrapyramidal side effects~ * Cardiac arrhythmias including QT prolongation (increased risk with the drugs listed in the appendix)~Exclusion Criteria:~* History of, or current, arrhythmias including ventricular tachycardia, ventricular fibrillation and Torsade des Pointes. Patients with minor forms of ectopy (PACs) are not necessarily excluded.~* Clinically significant bradycardia, sinus node dysfunction, or heart block. Prolonged QTc (QTc\>450 milliseconds for males, QTc\>470 milliseconds for females)~* Clinically significant electrolyte disorders. These include significant hypokalemia, hyperkalemia, hypomagnesemia, and hypermagnesemia that cannot be corrected with treatment of these electrolyte abnormalities.~* Gastrointestinal hemorrhage or obstruction.~* Presence of a prolactinoma (prolactin-releasing pituitary tumor).~* Pregnant or breast feedings female.~* Known allergy to domperidone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Domperidone (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Subcutaneous Mircera, Versus no Erythropoiesis-Stimulating Agent (ESA) Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* kidney transplant \>=6 months and \<5 years prior to randomization;~* anemia;~* no ESA therapy during 3 months prior to randomization.~Exclusion Criteria:~* requirement for hemodialysis or peritoneal dialysis within 3 months prior to randomization;~* change in Hb concentration \>=1.5g/dL during screening period;~* transfusion of red blood cells during 3 months prior to randomization;~* poorly controlled hypertension;~* significant acute or chronic bleeding within 3 months prior to randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Midline Catheter and Its Impact on Central Lines Removal in ICU

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18 years of age~* admitted to ICU since at least 48h~* with a perfusion CVC inserted~* requiring or having required invasive mechanical ventilation~* lack of formal indication to CVC maintenance (weaning of vasopressors and/or parenteral nutrition) since at least 24 hours~* indication to maintain a venous access~Exclusion Criteria:~* Lack of patient or next of kin consent~* Personnel for insertion of midline catheter not available~* Admission in ICU before study start~* Admission following a transfer from another ICU~* Patient with an implantable port or a peripherally inserted central catheter (PICC Line)~* Known intolerance to components of study Midline device~* Past history of irradiation of insert area of midline catheter~* Past history of bilateral axillary lymph node dissection~* Pre-existing skin infection on upper limb~* Patient with a treatment-limitation decision~* Patient admitted after cardiac arrest with non-shockable rhythm~* Moribund~* Pregnancy, breastfeeding woman~* Patient under legal guardianship~* Patient hospitalized without consent and/or deprived of liberty by court's decision

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Midline Catheter (Type: ACTIVE_COMPARATOR): Pt. will receive midline catheters.
- Standard Peripheral venous Catheter (Type: ACTIVE_COMPARATOR): Pt. will receive a standard Peripheral venous catheter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Aliskiren/Amlodipine and Amlodipine on Ankle Foot Volume (AFV) in Patients With Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients (male or female) with hypertension aged between 18-75 yrs.~* Patients not treated with amlodipine or no amlodipine in previous 1 year.~* Post-menopausal females~Exclusion Criteria:~* Patients unable to switch from prior hypertensive medication.~* Severe hypertension.~* Pregnant or nursing females.~* Patients with Type 1 or Type 2 diabetes mellitus~* History of immunodeficiency diseases, including a positive Human immunodeficiency virus (HIV) (Enzyme-linked immunosorbent assay \[ELISA\] and Western blot) test result.~* A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.~Other protocol-defined inclusion/exclusion criteria are applied

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Aliskiren/amlodipine + Placebo to amlodipine (Type: EXPERIMENTAL): During the first week of active treatment, patients were instructed to take one tablet of aliskiren/amlodipine 150/5 mg and one capsule of placebo to amlodipine daily. For the 2nd to 4th week of active treatment, the patients were up-titrated to take 2 tablets of aliskiren/amlodipine 150/5 mg/day and 1 capsule of placebo to amlodipine.~The patients were instructed to administer daily dose between 8:00 and 10:00 am preferably at the same time of the day.
- Amlodipine + Placebo to aliskiren/amlodipine (Type: ACTIVE_COMPARATOR): During the first week of active treatment, patients were instructed to take one capsule of amlodipine 5 mg and one tablet of placebo to aliskiren/amlodipine 150/5 mg daily. For the 2nd to 4th week of active treatment, the patients were up-titrated to take 1 capsule of amlodipine 10 mg/day and 2 tablets of placebo to aliskiren/amlodipine 150/5 mg/day.~The patients were instructed to administer daily dose between 8:00 and 10:00 am preferably at the same time of the day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Reinforced Staple Line on Leak Rate in Distal Pancreatectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must be 18 years or older and able to give consent. Any patient undergoing a distal pancreatectomy, laparoscopic or open, will be eligible for randomization.~* No exclusion is provided for primary diagnosis. In the event of a patient undergoing a planned resection of another organ or organs with only a possibility of a distal pancreatic resection (i.e. colectomy, hepatectomy, gastrectomy, nephrectomy), the patient will still be eligible for inclusion in the study. We expect that some patients will be randomized but not resected (ie metastasis identified). A few patients may not be stapled using the study device for technical reasons (ie the stapler does not fit). The data will be analyzed in an intent-to-treatment approach.~Exclusion Criteria: None specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stapled transection with mesh reinforcement (Type: ACTIVE_COMPARATOR): Mesh reinforced staple line (SEAMGUARD® or PERI-STRIPS DRY®)
- Stapled transection without mesh reinforcement (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Assessing the Safety/Efficacy of Transdermal Testosterone in Female Patients With Symptomatic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Female 50 years of age or older; post-menopausal (≥ 12 Mo/ from last menstruation)~* Documented left ventricular ejection fraction (LVEF) of 20-40% within 90 days prior to the baseline visit~* History of HF for more than 90 days and a diagnosis of symptomatic HF (Class III NYHA) for at least 30 days prior to the baseline visit~* Ambulatory (i.e., able to walk without assistance of another person or device such as cane or walker)~Exclusion Criteria:~* Neuromuscular or rheumatologic conditions that limit the to their ability to improve walking distance~* Pulmonary edema or multiorgan failure or cardiogenic shock within 30 days prior to the baseline visit~* Congenital heart disease, infiltrative myocardial disease~* Unstable angina or myocardial infarction within 30 days prior to the baseline visit~* Undiagnosed abnormal genital bleeding~* History of breast cancer, breast surgery, or breast disease contraindicating estrogen/hormone therapy~* Polycystic ovary syndrome or any other condition known to be adversely affected by testosterone treatment~* Resting heart rate \> 120 bpm~* Systolic blood pressure \> 180 mmHg or diastolic blood pressure \> 100 mmHg~* Known or suspected hypersensitivity or allergy to any adhesive or to any of the components of the testosterone transdermal system (TTS)~* Use of SERMS, SARMS, SPRMs, tibolone, testosterone, estrogen, progesterone agonists and antagonists or taking any prescription and over the counter medications/ nutraceuticals (eg, phyto-estrogens) that may have anabolic or steroid hormonal effects within 30 days prior to the baseline visit~* Use of marketed or investigational oral, sub-lingual, topical, transdermal injectable, or vaginal androgen therapy including dehydroepiandrosterone (DHEA) at any time within 3 months prior to the baseline visit~* Use of systemic corticosteroids within 30 days prior to the baseline visit (acute use for fewer than 7 days is acceptable)

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): placebo patch
- 300 µg/day testosterone (Type: EXPERIMENTAL): 300 micrograms/day transdermal testosterone patch
- 450 µg/day testosterone (Type: EXPERIMENTAL): 450 micrograms/day transdermal testosterone patch

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues